BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2024 6:47:30 AM | Browse: 123 | Download: 535
 |
Received |
|
2024-09-14 02:35 |
|
Peer-Review Started |
|
2024-09-14 02:35 |
|
First Decision by Editorial Office Director |
|
2024-10-15 21:32 |
|
Return for Revision |
|
2024-10-15 21:32 |
|
Revised |
|
2024-10-28 09:17 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-20 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-20 06:42 |
|
Articles in Press |
|
2024-11-20 06:42 |
|
Edit the Manuscript by Language Editor |
|
2024-11-27 00:42 |
|
Typeset the Manuscript |
|
2024-12-05 02:49 |
|
Publish the Manuscript Online |
|
2024-12-30 06:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Adrián Cortés-Martín and Julio Plaza-Diaz |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Julio Plaza-Diaz, PhD, School of Health Sciences, Universidad Internacional de La Rioja, Avenida de la Paz 137, Logrono 26006, La Rioja, Spain. julioramon.plaza@unir.net |
| Key Words |
Glucagon-like peptide 1 agonists; Liver diseases; Metabolic dysfunction-associated steatotic liver disease; Metabolic health; Pharmacotherapy; Diet; Gut microbiome; Physical exercise; Lifestyle; Non-alcoholic fatty liver disease |
| Core Tip |
This article comments on Soresi and Giannitrapani’s work concerning glucagon-like peptide 1 agonists as potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. The integration of dietary changes and regular physical exercise into treatment may improve patient outcomes. These lifestyle adjustments may reduce the reliance on pharmacological interventions and/or increase the effectiveness of existing treatments. Therefore, lifestyle factors should not be overlooked in the broader strategy for managing metabolic dysfunction-associated steatotic liver disease, since they complement medical therapies. |
| Publish Date |
2024-12-30 06:47 |
| Citation |
Cortés-Martín A, Plaza-Diaz J. Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders. World J Gastroenterol 2025; 31(4): 101436 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i4/101436.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i4.101436 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
